Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Injection entities : Eli lilly and company save search
Injection Pen Market Size is Projected To Reach USD 80,511.51 Million By 2031, Growing at a CAGR of 7.8% | Valuates Reports
Published: 2023-05-23 (Crawled : 14:00) - prnewswire.com
AZNCF | $135.94 770
|
Health Technology
|
| O: 0.7%
H: 1.22%
C: -0.67%
NONOF | $124.02 1.9K
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: -3.5%
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: -0.25%
H: 0.69%
C: -2.24%
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
AZN | $68.39 -0.5% 1.1M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: -1.46%
reach growing injection market
Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience
Published: 2022-08-08 (Crawled : 11:00) - prnewswire.com
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: -0.22%
H: 1.82%
C: 0.62%
taltz injection
Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)
Published: 2022-06-14 (Crawled : 01:00) - prnewswire.com
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: -0.49%
H: 0.98%
C: 0.56%
INCY | $53.88 0.84% 230K
|
Health Technology
|
| O: -2.09%
H: 0.41%
C: -1.96%
drug application injection
New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®
Published: 2022-06-06 (Crawled : 00:00) - prnewswire.com
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: 0.0%
treatment diabetes injection
Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market
Published: 2022-05-27 (Crawled : 15:20) - biospace.com/
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: 2.26%
H: 0.0%
C: 0.0%
injection market
Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio
Published: 2022-05-27 (Crawled : 13:00) - prnewswire.com
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: 2.26%
H: 0.0%
C: 0.0%
drug injection
Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022
Published: 2022-01-22 (Crawled : 00:20) - prnewswire.com
INCY | $53.88 0.84% 230K
|
Health Technology
| Email alert
Add to watchlist
LLY | $745.04 -0.76% 730K
|
Health Technology
| Email alert
Add to watchlist
tyvyt cel asco injection results biosimilar biomarkers
Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer who Progressed after EGFR-TKI Therapy
Published: 2021-12-24 (Crawled : 11:00) - prnewswire.com
INCY | $53.88 0.84% 230K
|
Health Technology
| Email alert
Add to watchlist
LLY | $745.04 -0.76% 730K
|
Health Technology
| Email alert
Add to watchlist
tyvyt new drug application drug cel lung cancer china therapy injection cancer biosimilar
Needle-Free Injections Market is Growing at a CAGR of 14.15% during the Forecast Period from 2021 to 2026 and will reach USD 24.12 billion by 2026, Affirms DelveInsight
Published: 2021-12-06 (Crawled : 17:00) - prnewswire.com
TRUMF | $16.504 1.7K
|
Health Technology
|
| O: 0.5%
H: 0.19%
C: -2.25%
TRUMY | $16.53 31K
|
Manufacturing
|
| O: 0.12%
H: 0.2%
C: 0.12%
WST | $376.36 -0.65% 90K
|
Health Technology
|
| O: -1.59%
H: 0.0%
C: 0.0%
NVO | $123.5 -0.32% 1M
|
Health Technology
|
| O: 1.0%
H: 0.0%
C: 0.0%
JNJ | $144.56 -2.05% 4.3M
|
Health Technology
|
| O: 1.49%
H: 0.0%
C: 0.0%
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: -2.2%
H: 0.0%
C: 0.0%
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
injection growing
Innovent Releases the ORIENT-31 Phase 3 Study First Interim Analysis Results of Sintilimab plus BYVASDA (bevacizumab biosimilar injection) and Chemotherapy in Patients with EGFR-mutated Nonsquamous Non-small Cell Lung Cancer who Progressed After EGFR-TKI Therapy at ESMO Virtual Plenary 2021
Published: 2021-11-22 (Crawled : 03:00) - prnewswire.com
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: -1.61%
H: 0.67%
C: -0.68%
INCY | $53.88 0.84% 230K
|
Health Technology
|
| O: -1.1%
H: 0.22%
C: -1.92%
lung cancer therapy injection results cancer phase 3 biosimilar
Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
ford test injection insulin
Global Gynecology Drugs Market Report 2021-2026: Focus on Cancers, Polycystic Ovary Syndrome, Contraception, Endometriosis, Female Infertility, Infections, Postmenopausal Disorders
Published: 2021-08-23 (Crawled : 16:00) - prnewswire.com
GSK | $39.935 -1.4% 900K
|
Health Technology
|
| O: -0.24%
H: 0.19%
C: -0.62%
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: 0.7%
H: 0.22%
C: -1.65%
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: 0.82%
H: 0.54%
C: -0.37%
ABT | $109.02 0.12% 1.7M
|
Health Technology
|
| O: 0.76%
H: 0.5%
C: -0.66%
TXMD | $1.9899 33K
|
Health Technology
|
| O: -0.51%
H: 7.79%
C: 4.07%
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: -0.28%
H: 0.09%
C: -0.59%
AZN | $68.39 -0.5% 1.1M
|
Health Technology
|
| O: -0.51%
H: 0.44%
C: -0.49%
AMGN | $264.99 -0.2% 410K
|
Health Technology
|
| O: -0.06%
H: 1.45%
C: 0.65%
cancer drug injection syndros contraceptive infections
FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps
Published: 2021-08-16 (Crawled : 12:00) - biospace.com/
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
fda injection insulin fda approval
Innovent Announces the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab biosimilar injection) as First-Line Therapy for People with Hepatocellular Carcinoma
Published: 2021-06-28 (Crawled : 01:00) - prnewswire.com
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: -0.53%
H: 0.38%
C: -0.34%
INCY | $53.88 0.84% 230K
|
Health Technology
|
| O: 1.49%
H: 0.16%
C: -2.85%
china therapy injection approval biosimilar
Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes
Published: 2021-06-25 (Crawled : 16:00) - prnewswire.com
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: 0.06%
H: 0.16%
C: -1.24%
diabetes results injection
Worldwide Injectable Drugs Industry to 2026 - Featuring Pfizer, GlazoSmithKline and Novartis Among Others
Published: 2021-06-10 (Crawled : 15:00) - prnewswire.com
JNJ | $144.56 -2.05% 4.3M
|
Health Technology
|
| O: 0.25%
H: 0.95%
C: 0.65%
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: 0.43%
H: 3.91%
C: 2.89%
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: 1.21%
H: 1.07%
C: 0.67%
AZN | $68.39 -0.5% 1.1M
|
Health Technology
|
| O: 0.94%
H: 1.27%
C: 1.2%
drug injection
Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
treatment phase 1 injection results cancer colorectal cancer phase 1b phase 2b
Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer
Published: 2021-06-03 (Crawled : 09:00) - prnewswire.com
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: -0.07%
H: 2.34%
C: 1.86%
lung cancer china therapy injection cancer approval gemcitabine
Insights on the Diabetes Injection Pens Global Market to 2027 - AstraZeneca, Biocon and Novo Nordisk Among Others
Published: 2021-05-11 (Crawled : 21:00) - prnewswire.com
NVO | $123.5 -0.32% 1M
|
Health Technology
|
| O: 0.73%
H: 1.3%
C: 1.11%
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: 0.0%
H: 0.46%
C: -0.8%
BDX | $232.67 -0.87% 180K
|
Health Technology
|
| O: -0.48%
H: 1.47%
C: 0.67%
AZN | $68.39 -0.5% 1.1M
|
Health Technology
|
| O: 1.15%
H: 0.55%
C: -0.4%
diabetes injection
Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021
Published: 2021-04-13 (Crawled : 01:00) - prnewswire.com
LLY | $745.04 -0.76% 730K
|
Health Technology
|
| O: -0.35%
H: 1.36%
C: 0.75%
treatment lung cancer injection results cancer phase 3
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PALI | $6.57 57.93% 19M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
PRSO | $1.79 40.95% 38M
|
Manufacturing
MCBC | $13.795 38.92% 820K
|
Finance
BTTR | $6.86 34.51% 5.2M
|
Manufacturing
SNGX | $0.51 32.09% 6.3M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.